Hua Medicine Begins Phase I Trial of Novel Diabetes Treatment
9/6/2013 12:32:14 PM
by Richard Daverman, PhD
September 6, 2013 -- Hua Medicine has begun a China Phase I clinical trial of a novel Glucokinase activator treatment for diabetes 2. The CFDA gave HMS5552, as the Hua drug is known, the designation of type 1.1 novel drug because no drug of the Glucokinase activator class has been approved anywhere in the world. Hua in-licensed China rights to the drug from Roche two years ago. In a statement, Dr. Li Chen, CEO of Hua Medicine, noted that it was a significant milestone for Hua to start clinical development in China of an innovative diabetes treatment that is intended for the world’s market. More details....
Help employers find you! Check out all the jobs and post your resume.